alpha-Galactosidase: Clinical Trials

7 trials of alpha-Galactosidase, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 unknown. 2 Early Phase 1, 2 Not applicable, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Early Phase 12Completed 2
Not applicable2Completed 1, Unknown 1
Phase 31Completed 1

Follow alpha-Galactosidase: new trials by email Literature Review of alpha-Galactosidase trials Research Report on alpha-Galactosidase

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Glycemic Response of Whole Beans and Bean Products
Alpha galactosidase, Placebo - Healthy, Body Mass Index, Normal
Early Phase 1CompletedIowa State University212023-03-282024-10-08
A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.
Enzyme Replacement Therapy (ERT) - Fabry Disease
CompletedAmicus Therapeutics822020-03-012026-02-05
Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease
Enzyme replacement therapy (Agalsidase alpha (Replagal®)), Magnetic Resonance Imaging - Anderson-Fabry Disease
Not applicableCompletedUniversity Hospital, Rouen262017-03-252026-04-17
Epidemiological Study of Fabry Disease in Taiwan Young Stroke Patients
GLA gene - Fabry Disease
UnknownChiayi Christian Hospital10002016-01-012018-07-23
The Effects of Added Enzyme α-Galactosidase at a Carbohydrate-rich Meal in Irritable Bowel Syndrome (IBS)
Alpha-Galactosidase - Irritable Bowel Syndrome
Early Phase 1CompletedSahlgrenska University Hospital202011-11-012014-11-18
Alpha-galactosidase Enzyme and Irritable Bowel Syndrome
Alpha-galactosidase - Irritable Bowel Syndrome
Not applicableUnknownVerman Oy Ab1502010-12-012011-01-17
Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease
Replagal - Fabry Disease
Phase 3CompletedShire352010-04-132021-06-08

Conditions studied

Fabry Disease (4)  ·  Irritable Bowel Syndrome (2)  ·  Dilatation, Pathologic (1)  ·  Hyperglycemia (1)  ·  Insulin Resistance (1)

Sponsors

Amicus Therapeutics (1)  ·  Chiayi Christian Hospital (1)  ·  Iowa State University (1)  ·  Sahlgrenska University Hospital (1)  ·  Shire (1)  ·  University Hospital, Rouen (1)  ·  Verman Oy Ab (1)

Countries

United States (3)  ·  Finland (2)  ·  Australia (1)  ·  Brazil (1)  ·  Czechia (1)  ·  France (1)  ·  Japan (1)  ·  Poland (1)  ·  Slovenia (1)  ·  Sweden (1)  ·  Taiwan (1)  ·  Turkey (Türkiye) (1)  ·  United Kingdom (1)

Top investigators

Jari Koskenpato, MD, PhD (1)

Results publications

PMID 26185417, PMID 39988522, PMID 40790487

NIH funding

2009 (1)